Telix Investors Alerted: Act by Jan. 9 in Suit Over SEC and FDA Findings
Hagens Berman, a prominent shareholder rights law firm, highlights a critical deadline for Telix Pharmaceuticals Ltd. (NASDAQ: TLX) investors concerning a securities class action lawsuit. The lawsuit stems from severe regulatory challenges, such as an SEC subpoena and an FDA Complete Response Lette…